Recent Posts
- Health Canada has approved an updated version of the NITISINONE TABLETS’ Product Monograph
- Cycle Pharmaceuticals and Catalent Partner to Develop Treatments for Rare Diseases using Zydis ODT Technology
- NITYR (nitisinone) Tablets for tyrosinaemia type 1 will be available with fully subsidised access on the Life Saving Drugs Program across Australia
- Cycle Pharmaceuticals’ NITYR (nitisinone) tablets receives marketing authorization in Chile
- Longer shelf life for NITYR (nitisinone) tablets for HT-1 in the U.S. granted by the FDA
Archives
- No comments have been published yet.
Find us on Facebook
Archives
Recent Posts
- Health Canada has approved an updated version of the NITISINONE TABLETS’ Product Monograph
- Cycle Pharmaceuticals and Catalent Partner to Develop Treatments for Rare Diseases using Zydis ODT Technology
- NITYR (nitisinone) Tablets for tyrosinaemia type 1 will be available with fully subsidised access on the Life Saving Drugs Program across Australia
- Cycle Pharmaceuticals’ NITYR (nitisinone) tablets receives marketing authorization in Chile
- Longer shelf life for NITYR (nitisinone) tablets for HT-1 in the U.S. granted by the FDA
Recent Comments